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Cerebral small vessel disease (CSVD) is a pathophysiological process
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involving small arteries such as cerebellar arteries, arterioles, capillaries,
and veinlets. Imaging features vary; they are mainly composed of recent
subcortical infarcts, lacunes of presumed vascular origin, white matter
hyperintensities (WMHs) of presumed vascular origin, cerebral microbleeds,
enlarged perivascular spaces, and global and regional brain atrophy.
CSVD is a common cause of vascular cognitive dysfunction, and in its
end stage, dementia often develops. CSVD has been a major research
hotspot; however, its causes are poorly understood. Neuroimaging
markers of CSVD can be used as the basis for etiological analysis. This
review highlights the relevance of neuroimaging markers and cognitive
impairment, providing a new direction for the early recognition,
treatment, and prevention of cognitive dysfunction in small cerebral
angiopathy.

1

Introduction

Cerebral small vessel disease (CSVD) refers to
the brain’s small vessels having lesions; these
lesions are noted on pathological examination or
brain imaging using magnetic resonance imaging
(MRI) or computed tomography (CT) [1]. Cognitive
impairment and even dementia in clinical end
stage may develop, but the pathogenesis is poorly
understood. The current total number of patients
with dementia worldwide is approximately
36 million, which is estimated to reach 66 million
Corresponding author: Jianhua Zhao, E-mail: zjh0913@163.com

by 2030 and increase to approximately 110 million
by 2050 [2]. In recent years, several studies found
that neuroimaging results are associated with
cognitive dysfunction, and can be used to predict
the progression of cognitive impairment. Jokinen
et al. [3] found that lacunes can cause impaired
executive function and reduce psychomotor
speed. A prospective cohort study [4] on 503
non-dementia patients aged 50–85 years with
CSVD showed that cerebral microbleed (CMB) was
associated with the early manifestation of cognitive dysfunction, particularly in non-dementia
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CSVD patients with satisfactory objective cognitive performance. This review will help in
understanding the relationship between various
imaging markers and cognitive dysfunction, and
provide new potential therapies and interventions
for the treatment of cognitive impairment.

2
2.1

Cerebral small vessel disease
Overview

Cerebrovascular disease is a serious threat to
human physical and mental health. It is characterized by high morbidity, high mortality, high
recurrence rate, and high disability rate. It is a
common cause of cerebral apoplexy, vascular
cognitive dysfunction, and dementia. CSVD is
a common clinical, imaging, and pathological
syndrome involving the brain’s small perforating
arteries, arterioles, capillaries, and venules [5]
and is a significant marker of cerebrovascular
disease. CSVD accounts for approximately 25%
of ischemic cerebrovascular diseases [6]. The
etiology, pathology, and risk factors of CSVD
have become a hot topic worldwide, and the
pathogenesis of CSVD remains controversial.
Different from common large vascular diseases,
CSVD often involves small blood vessels in the
brain. Anatomically, small blood vessels originate
in cerebral arteries, including the terminal
small artery, arteriole, arteriovenous anastomosis,
capillaries, micro vein, and terminal venules.
Small blood vessels nourish the basal ganglia and
deep white matter and mark the end of brain
blood circulation, also known as the terminal
artery [7]. This vascular wall lacks outer membrane
cells; it has vascular endothelial cells and a
small number of smooth muscle cells, which are
vulnerable to several factors, such as inflammation,
toxin, leading to vascular damage and injury to
the brain parenchyma, resulting in corresponding neurological symptoms and signs. Although
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vascular endothelial cells, smooth muscle cells,
peripheral cells, glial cells, and neurons constitute
the neurogliovascular unit and play a key role
in the pathogenesis of cerebral microvascular
disease, their mechanism is unclear.
Currently, CSVD diagnosis mainly depends on
imaging examination. The presentation of other
potential methods [8] increases the detection rate
of CSVD in the elderly year after year, gradually
attracting extensive attention from medical
researchers. Although the medical community
paid more attention on CSVD and has made
great achievements in the corresponding clinical
research, more studies to understand deeper
details are needed.
Whether the onset of CSVD is with individual
or collective is unclear, and the progress is slow.
Several studies in humans identified various
clinical manifestations of CSVD including
ischemic or hemorrhagic stroke, cognitive
impairment, dementia, abnormal gait, and
mental disorder. Studies have shown that CSVD
progression is associated with vascular risk
factors and the increase of CSVD load, whereas
cognitive dysfunction further aggravated.
Therefore, targeting vascular risk factors could
prevent CSVD-related brain injury and reduce
cognitive impairment [9].
2.2

Clinical pathological changes and types

Based on pathological changes, CSVDs can be
categorized into arteriosclerotic small vascular
diseases, sporadic and hereditary cerebral amyloid
angiopathy (CAA), inherited or genetic small
vessel diseases distinct from cerebral amyloid
angiopathy, inflammatory and immunologically
mediated small vessel diseases, radioactive
microangiopathy, venous collagenous disease,
and other small vessel diseases [10, 11], with
arteriolosclerosis and cerebral amyloid angiopathy
as common types.
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Arteriolosclerosis pathological changes include
fibrinoid necrosis, microatheroma, microaneurysms, and segmental arterial disorganization. The
pathological feature of CAA is the accumulation
in small blood vessels of the cerebral cortex and
pia mater [12], with the vessel wall thickened and
the lumen narrowed, occluded, or dilated. They
also occur in these diseases: cerebral autosomal
dominant arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL), cerebral
autosomal recessive arteriopathy with subcortical
infarcts and leukoencephalopathy (CARASIL),
hereditary multi-infarct dementia of the Swedish
type, MELAS syndrome (mitochondrial myopathy,
encephalopathy, lactic acidosis, and stroke-like
episodes), Fabry’s disease, hereditary endotheliopathy with retinopathy, nephropathy, stroke,
small vessel diseases caused by COL4A1 mutations
constitute inherited or genetic small vessel
diseases, inflammatory and immunologically mediated small vessel diseases including Wegener’s
granulomatosis, Churg–Strauss syndrome, microscopic polyangiitis, Henoch–Schönlein purpura,
and cryoglobulinemic vasculitis.
2.3

Pathogenesis

The pathogenesis of CSVD is unclear, and how it
leads to the occurrence and development of CSVD
remains inadequately understood. Endothelial
dysfunction can cause increased permeability of
the blood–cerebrospinal fluid (CSF) barrier which
aggravates parenchymal injury [13]. Poggesi et al.
[14] detected blood–CSF barrier defects in CSVD
animal models with chronic cerebral perfusion
insufficiency, suggesting that the blood–brain
barrier (BBB) function may be impaired due to
endothelial dysfunction and secondary inflammatory changes. Recent studies [15] suggested
that vascular endothelial dysfunction caused by
inflammatory mechanism and oxidative stress
may be noted in cases with white matter lesions.
Inflammatory reactions that are a cascade

amplification process of and around the ischemic
foci after cerebral ischemia were determined.
Keith et al. [16] found that collagen deposition
caused interstitial fluid reflux obstruction and
increased vascular resistance, leading to cerebral
perfusion insufficiency, which plays a role in
the occurrence and development of CSVD. The
pathogenesis of CSVD which may be related to
factors such as BBB disruption, genetic factors,
chronic ischemia, and inflammatory response has
not been completely described
2.3.1

Blood–brain barrier disruption

The BBB is located between the plasma and brain
cells (formed by the capillary wall of the brain
and glial cells), and between the plasma and CSF
(formed by the choroid plexus), potentially preventing some substances (mostly harmful) from
entering the brain tissue through the blood. The
barrier mainly has three layers, from the inside
to the outside: the endothelial cells of cerebral
capillaries, the basal membrane, and the end foot
of glial cells. Besides oxygen, carbon dioxide, and
blood glucose, nothing can pass through the
BBB. Most molecular drugs and proteins are too
big to pass through the barrier.
The exact pathogenesis of CSVD is unclear, but
some studies [17] have shown that blood–CSF
barrier dysfunction is one of its causes. Poggesi
et al. suggested that impaired cerebral small
vessels may be due to endothelial dysfunction
and secondary inflammatory changes [18]. The
endothelial cells and basal membrane are continuous and closely connected to each other,
making it difficult for certain substances in the
blood to pass through. The end feet of glial cells are
located around capillaries, blocking the passage
of certain substances from blood vessel walls to
the brain tissue. Petersen et al. reported [19] that
certain blood components can pass through the
impaired BBB, activating microglia, recruiting
surrounding macrophages, and promoting
Journal of Neurorestoratology
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inflammation. A study [20] showed that BBB can
be destroyed, and blood components then leak
into the brain, impairing the normal neuronal
function. A study conducted by Topakian et al.
[21] showed that endothelial dysfunction can
impair blood vessel function and blood flow
regulation, leading to tissue damage.
2.3.2

Genetic factors

Genetic factors, especially genotype, are also the
focus of current research. Studies suggested [22]
that mutations may affect hereditary and nonhereditary CSVDs. CSVD is associated with cerebral
hypoperfusion, chronic ischemia, endothelial
dysfunction, genetic factors, and inflammatory
response [23]. Although vascular endothelial cells,
smooth muscle cells, peripheral cells, glial cells,
and neurons constitute the neurogliovascular
unit and play a key role in cerebral microvascular
disease pathogenesis, the mechanism is unclear.
A genome-wide association study [24] of 2230
white people demonstrated that the gene responsible for the effect of loose white matter size was
located on chromosome 4.
2.3.3

Hypoperfusion and ischemia

Chronic ischemia/hypoperfusion plays a key role
in CSVD pathogenesis. Cerebral arterioles are
mostly terminal arteries prone to hypoperfusion
and ischemia in an injured area [25]. Hypertension is the key factor of the condition, mainly
because it poses a small vascular lumen in the
brain, wherein chronic hypoperfusion of the white
matter is likely, resulting in neuronal apoptosis,
selective oligodendrocyte death, and myelin fiber
degeneration that lead to CSVD [26]. Several
scholars [27] also found that limb remote ischemic
preconditioning can induce cerebral ischemia
tolerance, which has a potential protective effect
on CSVD patients and is indirectly related to
chronic cerebral ischemia. Researchers found
that in cerebral ischemia or hypoperfusion, the
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supply of glucose, oxygen, and other nutrients
to the nervous system may be reduced, resulting
in damage or death of neurons due to lack of
energy, resulting in impaired neuronal function
and triggering CSVD [10].
2.4

Imaging of cerebral small vessel disease

With the rapid development of modern medical
imaging technology, imaging features vary, mainly
include recent subcortical infarcts, lacunes of
presumed vascular origin, white matter hyperintensities (WMHs) of presumed vascular origin,
CMB, enlarged perivascular spaces, and full
and regional brain atrophy. Imaging changes are
often found in patients with small cerebral vessels,
and MRI is often used to detect small blood
vessel damage in the brain.
In recent years, MRI has been widely used in
CSVD diagnosis and has provided ideal results.
Neuroimaging markers are a potential independent risk factor for CSVD. A study showed that
MRI manifestations are related to the cognitive
dysfunction in patients with CSVD [28]. There has
been a considerable increase in the application
of brain imaging in the studies of CSVD [29].

3

Cognitive impairment

Cognitive impairment refers to severe problems
in pathological process of learning and memory
accompanied by aphasia, agnosia, and disuse,
caused by abnormal brain senior intelligence
processing related to learning, memory, thinking,
and judgment. Vascular cognitive impairment
(VCI) has three clinical subtypes, namely, mild
cognitive impairment (MCI), vascular dementia
(VaD), and mixed dementia [30].
In 1995, Bowler et al. proposed that VCI is the
only cognitive impairment type that can be
prevented and controlled during the mild stage
[31]. Overton et al. [32] thought that MCI is a
diverse condition as the prevalence and incidence
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estimates differed substantially according to age,
MCI subtype, and cognitive impairment severity
that the prevalence estimates ranged from 5.13%
to 29.9% depending on age and severity of impairment. Moreover, executive function is a
recognized feature. In addition, there may be
attentional impairment, however the retention
relatively remains [32, 33].
Dementia is caused by several factors. Cerebrovascular disease is the second common cause
of senile cognitive impairment and dementia,
and CSVD accounts for a large proportion in
cerebrovascular disease. O’Brien et al. also noted
that the incidence of dementia in the general
population of over age 65 is approximately 7%
and the condition is twice as common. The
morbidity of MCI is high; thus, it should be
detected early, and effective prevention and treatment should be done to minimize the incidence
of dementia.

4

Cerebral small vessel disease and
cognitive impairment

4.1 Recent subcortical infarcts and cognitive
impairment
The centrum semiovale, basal ganglia, corona
radiata, and brain stem are the recent areas of infarctions in the brain. Its maximum axial diameter
is generally less than 20 mm, but the diameter on
the coronal plane may be above 20 mm. Long T1
and long T2 signals were noted, fluid-attenuated
inversion recovery (FLAIR) sequences showed
hyperintensity, and diffusion-weighted imaging
revealed hyperintensity on brain MRI [34].
Lesions in the posterior horn of the inner
capsule were associated with impaired executive
function, whereas lesions in the frontal lobe were
associated with impaired memory and executive
function, coding, and information management.
Temporal lobe lesions are related to memory,

language, hearing, and affective disorders. Moreover, anterior thalamus lesions are associated
with amnesia [35]. Studies have shown that the
number and volume of infarcts is an independent
predictor of processing speed and executive function impairment [36].
4.2

Lacunes and cognitive impairment

Lacune is a round or oval fluid-filled cavity in
the small perforating artery infarction and
hemorrhage. The lacune usually has a diameter
of 3–15 mm [37]. T2-FLAIR is characterized by a
low signal of the central CSF and the periphery
surrounded by the high-signal ring. The maximum
diameter of lacunar lesions was estimated to be
less than 15 mm, different from the 20 mm defined
diameter for recent subcortical infarcts [1].
The frontal, temporal, parietal, and occipital
lobes are the cortical centers of memory, language,
execution, and motor and visual space, respectively. Most studies [38] showed that post-lacune
cognitive impairment involved multiple cognitive
domains, including information-processing speed,
attention, executive function, memory, language,
and visuospatial function. The Leukoaraiosis and
Disability Study (LADIS study) [39] demonstrated on MRI that lacunes correspond a steeper
rate of decline in executive functions and psychomotor speed. The basal ganglia has extensive and
complex fiber connections with each cortex. Thong
et al. [40] found that damage to connecting fiber
bundles between the white matter of the brain
and corresponding brain regions could lead
to cognitive impairment. Moreover, disrupted
extensive fibrous connections were found between
the anterior medial thalamus and the orbitofrontal,
and prefrontal cortex decrease the processing
speed [41]. A meta-analysis [42] showed that
even small amounts of lacune can cause cognitive
impairment. An explanation [43] to this is that
infarction increases the risk of dementia.
Furthermore, lacunes, with location and quantity
Journal of Neurorestoratology
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closely related to the severity and type of cognitive impairment, may lead to the disruption of
specific cognitive function circuits in the brain,
leading to the dysfunction of attention and
information-processing speed barriers.
4.3 White matter hyperintensities and cognitive
impairment
WMHs are deep brain or patchy or dotted highsignal areas around a ventricle in T2-weighted
imaging or FLAIR. It is a clinical syndrome
characterized by diffuse patchy or patchy changes
of white matter in the lateral ventricle and the
center of the semi-oval on CT, whereas it is a T1weighted low signal in white matter around the
lateral ventricle on MRI, basically symmetrical
on both sides [44]. WMH usually occurs in the
lateral ventricle and the center of hemispheres.
The CSF with a low central signal and a high
peripheral signal was observed in the FLAIR
phase.
Based on different imaging sites, white matter
hypersignals can be categorized into periventricular white matter hypersignals (PVH) and subcortical deep white matter hyperintensity (SDWMH)
[45]. The following are the SDWMH grades [46]:
Level 0, normal MRI;
Level 1, abnormal high point signal;
Level 2, abnormally high patchy signal (fusion
tendency between lesions) or single lesion diameter greater than 3 mm;
Level 3, lamellar and abnormally high signal
(interfusion of lesions).
PVH grades [46] are as follows:
Level 0, normal MRI;
Level 1, abnormal high signal of lateral ventricle frontal angle and / or occipital angle cap;
Level 2, abnormal high signal of lunar halo
around the lateral ventricle;
Level 3, the anomalous signal extends to the
deep white matter.
Mortamais et al. [47] reported that white matter
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lesions are associated with decreased cognitive
function. Studies [39, 48, 49] have shown that
white matter impairment is closely related to
stroke, cognitive and affective disorders, dementia,
gait and urination difficulties, and especially
cognitive impairment and dementia. WMHs
were associated with an increased dementia in
the general middle-aged and elderly population
[50, 51]. Therefore, WMH may be a predictor of
vascular cognitive dysfunction.
4.4

Cerebral microbleeds

CMBs are parenchymal subclinical lesions
characterized by tiny hemorrhages and appear
primarily in small cerebral vessels [52]. Consensus
manifests the definition of CMBs is as follows [8]:
(1) a small round or ovoid shape, distinct
border, homogeneity, and signal missing stove;
(2) diameter < 10 mm (generally 2−5 mm);
(3) surrounded by brain parenchyma;
(4) T2GRE sequence showed blooming effect;
(5) T1 and T2 sequences of corresponding parts
have no high signal;
(6) identification of bone vessel empty with
iron and calcium deposition;
(7) diffuse axonal injury caused by trauma was
excluded.
Poels et al. [53] reported that CMBs can
gradually cause psychosocial symptoms, cognitive
dysfunction, and dementia. Gormley et al. [54]
have shown that the incidence of CMBs is 16%–
45%, among which the cognitive impairment is
the most important trait. In the autopsy results of
1143 elderly patients, Arvanitakis et al. [55] found
that the incidence of arterial atherosclerosis
was up to 54% and its severity was positively
correlated with cognitive dysfunction severity.
CMBs may be associated with hypertensive
vascular damage. Li et al. [56] conducted a metaanalysis on 25 studies involving 9343 patients,
and the results revealed that the higher the
number of microhemorrhage is, the lower the
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clinical score of mini-mental state examination is,
the slower the information-processing speed
and behavior of the patient are. Akoudad et al.
[57] indicated that cerebral lobe CMBs were
associated with decreased executive function
information processing and memory, whereas
deep CMBs affected motor function.
In summary, the cognitive impairment caused
by CMBs depends on various factors, including
the size, number, distribution, and location of
CMB lesions and the presence or absence of other
associated diseases.
4.5

Enlarged perivascular spaces

Perivascular spaces, also known as Virchow–Robin
spaces (VRS), are normal anatomical structures
that have certain physiological and immune
functions. It is the space between the blood
vessels in the brain and the soft meninges filled
with CSF. The basal ganglia area or the center of
the semi-oval is circular or elliptic and dotted or
linear, similar to the signal of the CSF. T1-weighted
imaging (T1WI) and FLAIR sequences have low
signals, whereas T2-weighted imaging (T2WI)
has a high signal. Enlarged perivascular spaces
(EPVS) have three characteristic sites [58]:
Type 1, the anterior transposition of the zona
pellucida into the basal ganglia;
Type 2, the subcortical white matter that the
convex surface and deep of the brain, the medullary artery, enters;
Type 3, the brainstem.
Many studies determined a strong correlation
between increased perivascular clearance and
cognitive impairment. Based on clinical study
results, Ding et al. [59] reported that 3-mm EPVS
was associated with cognitive decline and
vascular dementia. Maclullich et al. [60] showed
that EPVS may lead to nerve fiber destruction
in the basal ganglia associated with cognitive
functions, resulting in the reduction of nonverbal
reasoning and visuospatial ability. The study [61]

found that increased perivascular space in the
center of the semi-oval and basal ganglia can
indicate subcortical vascular cognitive dysfunction. Thus, EPVS is also associated with cognitive
dysfunction.
4.6

Atrophy

Cerebral atrophy is the reduction of brain volume
not correlated with specific focal brain injury
such as cerebral infarction and hemorrhage
surgery. Numerous studies have shown that
brain atrophy can affect cognition.
Frontotemporal gray matter volume, hippocampal atrophy, and whole-brain atrophy were
associated with memory loss [62]. A cohort
study [63] found that progressive brain atrophy
is related to decreased cognitive function.
Tong et al. [64] found that the slowing down of
brain circulation and nutritional disorders in
brain atrophy patients led to decreased excitatory
neurotransmitters, degeneration of neurons, and
demyelination, which will lead to cognitive
decline. In a study by Cao et al. [65], 30.2% (13/43)
of CSVD patients showed a moderate to severe
atrophy of the medial temporal lobe. In some
CSVD patients, MRI revealed gyrus narrowing,
sulcus deepening, and ventricle enlargement, and
cortical atrophy was related to the severity of
CSVD [66]. A study [67] that included 35 CSVD
patients showed that brain volume was closely
related to executive function.
To summarize, brain atrophy was closely related
to cognitive dysfunction, which can be considered as a risk factor for CSVD.

5

Conclusion

It is clearly that CSVD is a common contributor
to stroke, functional decline, VCI, dementia, and
is also a significant risk factor for VCI and dementia. This report summarized recent advances
in the pathogenesis of CSVD, and CSVD and
Journal of Neurorestoratology
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cognitive impairment using neuroimaging
markers. Although their pathogeneses vary, they
have similar neuroimaging markers that can be
used as the basis for etiological analysis [68]. In
recent years, the linkages between CSVD and MCI
have attracted much interest. These neuroimaging markers provide new opportunities for the
evaluation of the relationship between CSVD and
cognitive impairment.
Therefore, CSVD was found to be associated
with an increased risk of dementia in the general
population. Considering the imaging results
of CSVD, it is important to evaluate the role of
stroke prevention in the prevention of cognitive
decline. Combined with the imaging manifestations of CSVD lesions, strategies to prevent cognitive decline are needed. This review highlights
that the correlation between MCI and imaging
markers of CSVD should be paid more attention
to provide new ideas for potential treatments
and interventions for cognitive impairment, and to
explore the relationship between CSVD and cognitive dysfunction, to provide theoretical reference
for early clinical prevention and treatment, which
in turn, can predict the damage degree of CSVD.
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